No Cover Image

Journal article 425 views

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib

Axel Bex, Peter Mulders, Michael Jewett, John Wagstaff, Johannes V. van Thienen, Christian U. Blank, Roland van Velthoven, Maria del Pilar Laguna, Lori Wood, Harm H. E. van Melick, Maureen J. Aarts, J. B. Lattouf, Thomas Powles, Igle Jan de Jong, MD, PhD, Sylvie Rottey, Bertrand Tombal, Sandrine Marreaud, Sandra Collette, Laurence Collette, John Haanen

JAMA Oncology, Volume: 5, Issue: 2, Start page: 164

Swansea University Author: John Wagstaff

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1001/jamaoncol.2018.5543

Abstract

This was a randomised phase II trial of immediate versus deferred nephrectomy in patients who were diagnosed with metastatic renal cancer with the primary cancer still in situ. Patients were randomised to have and up-front nephrectomy followed by sunitinib or three cycles of sunitinib followed by ne...

Full description

Published in: JAMA Oncology
ISSN: 2374-2437
Published: 2019
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa50641
first_indexed 2019-06-05T11:08:04Z
last_indexed 2019-06-18T20:51:17Z
id cronfa50641
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2019-06-18T14:05:30.6152918</datestamp><bib-version>v2</bib-version><id>50641</id><entry>2019-06-04</entry><title>Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2019-06-04</date><deptcode>MEDS</deptcode><abstract>This was a randomised phase II trial of immediate versus deferred nephrectomy in patients who were diagnosed with metastatic renal cancer with the primary cancer still in situ. Patients were randomised to have and up-front nephrectomy followed by sunitinib or three cycles of sunitinib followed by nephrectomy. Patients continued sunitinib after nephrectomy. Deferred nephrectomy did not improve the 28 week progression free rate. However the median survival of the patients in the deferred nephrectomy arm was 32.4 months in the deferred nephrectomy arm and 15 months in the immediate nephrectomy arm. These data suggest that sunitinib followed by deferred nephrectomy may identify a group of patients with inherent resistance to systemic therapy and who do not benefit from immediate nephrectomy.</abstract><type>Journal Article</type><journal>JAMA Oncology</journal><volume>5</volume><journalNumber>2</journalNumber><paginationStart>164</paginationStart><publisher/><issnPrint>2374-2437</issnPrint><keywords>renal cancer, sunitinib, nephrectomy</keywords><publishedDay>1</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2019</publishedYear><publishedDate>2019-02-01</publishedDate><doi>10.1001/jamaoncol.2018.5543</doi><url/><notes>The author was UK principle investigator for this clinical trial.</notes><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2019-06-18T14:05:30.6152918</lastEdited><Created>2019-06-04T21:38:10.9170869</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Axel</firstname><surname>Bex</surname><order>1</order></author><author><firstname>Peter</firstname><surname>Mulders</surname><order>2</order></author><author><firstname>Michael</firstname><surname>Jewett</surname><order>3</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>4</order></author><author><firstname>Johannes V.</firstname><surname>van Thienen</surname><order>5</order></author><author><firstname>Christian U.</firstname><surname>Blank</surname><order>6</order></author><author><firstname>Roland</firstname><surname>van Velthoven</surname><order>7</order></author><author><firstname>Maria</firstname><surname>del Pilar Laguna</surname><order>8</order></author><author><firstname>Lori</firstname><surname>Wood</surname><order>9</order></author><author><firstname>Harm H. E.</firstname><surname>van Melick</surname><order>10</order></author><author><firstname>Maureen J.</firstname><surname>Aarts</surname><order>11</order></author><author><firstname>J. B.</firstname><surname>Lattouf</surname><order>12</order></author><author><firstname>Thomas</firstname><surname>Powles</surname><order>13</order></author><author><firstname>Igle Jan</firstname><surname>de Jong, MD, PhD</surname><order>14</order></author><author><firstname>Sylvie</firstname><surname>Rottey</surname><order>15</order></author><author><firstname>Bertrand</firstname><surname>Tombal</surname><order>16</order></author><author><firstname>Sandrine</firstname><surname>Marreaud</surname><order>17</order></author><author><firstname>Sandra</firstname><surname>Collette</surname><order>18</order></author><author><firstname>Laurence</firstname><surname>Collette</surname><order>19</order></author><author><firstname>John</firstname><surname>Haanen</surname><order>20</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2019-06-18T14:05:30.6152918 v2 50641 2019-06-04 Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2019-06-04 MEDS This was a randomised phase II trial of immediate versus deferred nephrectomy in patients who were diagnosed with metastatic renal cancer with the primary cancer still in situ. Patients were randomised to have and up-front nephrectomy followed by sunitinib or three cycles of sunitinib followed by nephrectomy. Patients continued sunitinib after nephrectomy. Deferred nephrectomy did not improve the 28 week progression free rate. However the median survival of the patients in the deferred nephrectomy arm was 32.4 months in the deferred nephrectomy arm and 15 months in the immediate nephrectomy arm. These data suggest that sunitinib followed by deferred nephrectomy may identify a group of patients with inherent resistance to systemic therapy and who do not benefit from immediate nephrectomy. Journal Article JAMA Oncology 5 2 164 2374-2437 renal cancer, sunitinib, nephrectomy 1 2 2019 2019-02-01 10.1001/jamaoncol.2018.5543 The author was UK principle investigator for this clinical trial. COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University 2019-06-18T14:05:30.6152918 2019-06-04T21:38:10.9170869 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Axel Bex 1 Peter Mulders 2 Michael Jewett 3 John Wagstaff 4 Johannes V. van Thienen 5 Christian U. Blank 6 Roland van Velthoven 7 Maria del Pilar Laguna 8 Lori Wood 9 Harm H. E. van Melick 10 Maureen J. Aarts 11 J. B. Lattouf 12 Thomas Powles 13 Igle Jan de Jong, MD, PhD 14 Sylvie Rottey 15 Bertrand Tombal 16 Sandrine Marreaud 17 Sandra Collette 18 Laurence Collette 19 John Haanen 20
title Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
spellingShingle Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
John Wagstaff
title_short Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
title_full Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
title_fullStr Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
title_full_unstemmed Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
title_sort Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
author_id_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6
author_id_fullname_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff
author John Wagstaff
author2 Axel Bex
Peter Mulders
Michael Jewett
John Wagstaff
Johannes V. van Thienen
Christian U. Blank
Roland van Velthoven
Maria del Pilar Laguna
Lori Wood
Harm H. E. van Melick
Maureen J. Aarts
J. B. Lattouf
Thomas Powles
Igle Jan de Jong, MD, PhD
Sylvie Rottey
Bertrand Tombal
Sandrine Marreaud
Sandra Collette
Laurence Collette
John Haanen
format Journal article
container_title JAMA Oncology
container_volume 5
container_issue 2
container_start_page 164
publishDate 2019
institution Swansea University
issn 2374-2437
doi_str_mv 10.1001/jamaoncol.2018.5543
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 0
active_str 0
description This was a randomised phase II trial of immediate versus deferred nephrectomy in patients who were diagnosed with metastatic renal cancer with the primary cancer still in situ. Patients were randomised to have and up-front nephrectomy followed by sunitinib or three cycles of sunitinib followed by nephrectomy. Patients continued sunitinib after nephrectomy. Deferred nephrectomy did not improve the 28 week progression free rate. However the median survival of the patients in the deferred nephrectomy arm was 32.4 months in the deferred nephrectomy arm and 15 months in the immediate nephrectomy arm. These data suggest that sunitinib followed by deferred nephrectomy may identify a group of patients with inherent resistance to systemic therapy and who do not benefit from immediate nephrectomy.
published_date 2019-02-01T07:45:21Z
_version_ 1821390690250129408
score 11.364387

Similar Items